Hyperimmune globulins and same‐day thrombotic adverse events as recorded in a large healthcare database during 2008–2011
Open Access
- 1 August 2013
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 88 (12), 1035-1040
- https://doi.org/10.1002/ajh.23559
Abstract
Thrombotic events (TEs) are rare serious complications following administration of hyperimmune globulin (HIG) products. Our retrospective claims‐based study assessed occurrence of same‐day TEs following administration of HIGs during 2008–2011 and examined potential risk factors using HealthCore's Integrated Research Database (HIRDSM) and laboratory testing of products' procoagulant Factor XIa activity by U.S. Food and Drug Administration. Multivariable regression was used to estimate same‐day TE risk for different products. Of 101,956 individuals exposed to 23 different HIG product groups, 86 (0.84 per 1,000 persons) had a TE diagnosis code (DC) recorded on the same day as HIG administration. Unadjusted same‐day TE DC rates (per 1,000 persons) ranged from 0.4 to 148.9 for different products. GamaSTAN S/D IG >10 cc had statistically significantly higher same‐day TE DC risk compared to Tetanus IG (OR = 57.57; 95% CI = 19.72–168.10). Increased TE risk was also observed with older age (≥45 years), prior thrombotic events, and hypercoagulable state(s). Laboratory investigation identified elevated Factor XIa activity for GamaSTAN S/D, HepaGam B, HyperHep B S/D, WinRho SDF, HyperRHO S/D full dose, and HyperTET S/D. Our study, for the first time, identified increase in the same‐day TE DC risk with GamaSTAN S/D IG >10 cc and suggests potentially elevated TE risk with other HIGs. Am. J. Hematol. 88:1035–1040, 2013.This publication has 36 references indexed in Scilit:
- Passive immunization: the forgotten arm of immunologically based strategies for disease containmentAmerican Journal of Obstetrics and Gynecology, 2011
- Unlabeled uses of intravenous immune globulinAmerican Journal of Health-System Pharmacy, 2008
- Safety of IGIV therapy and infusion-related adverse eventsImmunologic Research, 2007
- Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory DisordersAnnals of Pharmacotherapy, 2007
- IGIV: Contents, properties, and methods of industrial production—evolving closer to a more physiologic productInternational Immunopharmacology, 2006
- Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and ImmunologyJournal of Allergy and Clinical Immunology, 2006
- The Patient: Emerging Clinical Applications of Intravenous ImmunoglobulinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005
- Risks associated with the use of intravenous immunoglobulinTransfusion Medicine Reviews, 2003
- Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune GlobulinThe New England Journal of Medicine, 2001
- Is there a place for hyperimmune globulins in the treatment of refractory infections?Transfusion Medicine Reviews, 2001